| 000 | 02581 a2200757 4500 | ||
|---|---|---|---|
| 005 | 20250515063857.0 | ||
| 264 | 0 | _c20070511 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/1471-2407-7-63 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, Kyung-Hun | |
| 245 | 0 | 0 |
_aPrognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. _h[electronic resource] |
| 260 |
_bBMC cancer _cApr 2007 |
||
| 300 |
_a63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aBreast Neoplasms _xchemistry |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aGenes, bcl-2 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKi-67 Antigen _xanalysis |
| 650 | 0 | 4 | _aLymph Node Excision |
| 650 | 0 | 4 | _aMastectomy, Modified Radical |
| 650 | 0 | 4 | _aMastectomy, Segmental |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xanalysis |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xanalysis |
| 650 | 0 | 4 |
_aReceptors, Progesterone _xanalysis |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTamoxifen _xadministration & dosage |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xanalysis |
| 700 | 1 | _aIm, Seock-Ah | |
| 700 | 1 | _aOh, Do-Youn | |
| 700 | 1 | _aLee, Se-Hoon | |
| 700 | 1 | _aChie, Eui Kyu | |
| 700 | 1 | _aHan, Wonshik | |
| 700 | 1 | _aKim, Dong-Wan | |
| 700 | 1 | _aKim, Tae-You | |
| 700 | 1 | _aPark, In Ae | |
| 700 | 1 | _aNoh, Dong-Young | |
| 700 | 1 | _aHeo, Dae Seog | |
| 700 | 1 | _aHa, Sung Whan | |
| 700 | 1 | _aBang, Yung-Jue | |
| 773 | 0 |
_tBMC cancer _gvol. 7 _gp. 63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2407-7-63 _zAvailable from publisher's website |
| 999 |
_c16981283 _d16981283 |
||